Anti-CD55 x Anti-HLA-A Bispecific Antibody (IgG-IgG) (BSIG-124)

Anti-CD55 x Anti-HLA-A Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CD55 and anti-HLA-A parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can recruit complements to tumor cells. It is designed for the research of Renal cell cancer (RCC); Solid tumors therapy.

Datasheet

Specifications

Targets

CD55 & HLA-A

Type

IgG-IgG

Species Reactivity

Human

Target 1

CD55

Host Animal 1

Mouse

Target 2

HLA-A

Host Animal 2

Mouse

Application

FuncS; Promising therapeutic agent

Related Disease

Renal cell cancer (RCC); Solid tumors

Targets

Target 1

CD55

Gene ID

1604

UniProt ID

P08174

Alternative Names

CD55; CD55 molecule, decay accelerating factor for complement (Cromer blood group); CR; TC; DAF; CROM; complement decay-accelerating factor; CD55 antigen

Target 2

HLA-A

Gene ID

3105

UniProt ID

P30443

Alternative Names

HLA-A; major histocompatibility complex, class I, A; HLAA; HLA class I histocompatibility antigen, A-1 alpha chain; antigen presenting molecule; leukocyte antigen class I-A; MHC class I antigen HLA-A heavy chain

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Welcome! For price inquiries, we will get back to you as soon as possible.

To order, please email

INQUIRY

Online Inquiry

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:

UK
167-169 Great Portland Street, 5th Floor, London, W1W 5PE
Tel: 44-207-097-1828
Email: